Allergan to acquire Motus Therapeutics for $200m

28-10-2016

Allergan to acquire Motus Therapeutics for $200m

maradon 333 / shutterstock.com

Allergan will acquire biopharmaceutical company Motus Therapeutics, a wholly-owned subsidiary of Rhythm Holding Company, for $200 million.


Allergan, Motus Therapeutics, mergers and acquisition, Relamorelin, gastrointestinal

LSIPR